Biotech

HEMO’s investment case is much strengthened since January, though the immediate cash issues remain a concern. my thoughts below. Hemogenyx. It’s been a while since I covered this oncology portfolio stock — last running through the investment case in late January 2023. I’d encourage would-be investors who are new to the company to briefly scan […]

Oxford Biodynamics shares have shot up, and deservedly so. However, there will likely be a pullback for a better entry point. Oxford Biodynamics (LON: OBD) shares were changing hands for as much as 278p five years ago and had collapsed to circa 10.5p towards the end of September 2023. The share has now shot up […]

Cizzle shares now look decent value for long-term investors — a strong component for the biotech portfolio. Read the condensed update below. With a slew of AIM companies reporting results — I thought it would be a good idea to take a brief look at Cizzle for the first time since late February. Alongside Avacta […]

Key things you need to know about investing in small cap oncology research stocks — including the best biotech on the AIM market. As a freelance financial analyst, I spend most of my time evaluating EIS-qualifying companies for high net worth investors, alongside coverage of market titans for blue chip clients. Much of this material […]

As with every article featured here, none of this is investing or financial advice. We encourage you to conduct your own research. Here at Investing Strategy, we like to cover high-risk, high-reward shares in select sectors which provide the best opportunities in relatively short time frames. One of these sectors is biotechs (or life sciences) […]

ABDX is shortly launching a world-first saliva pregnancy test. It could become the global standard. Abingdon Health (LON: ABDX) shares have shot up by over 100% year-to-date as investors in the FTSE AIM biotech are finally starting to see some light at the end of the tunnel. The company put to bed a hotly contested […]

Cizzle is advancing operations in both the US and China. This recent share price surge may continue into March. Cizzle Biotechnology (LON: CIZ) is presenting at the Biomarkers conference in Manchester this morning, marking the latest development in a line of good news over the past few months. Up 91% year-to-date to 2.96p, the biotech […]

Multiple promising treatments at the pre-clinical stage biotech stock could make it a solid speculative investment for 2023 and beyond. Hemogenyx Pharmaceuticals (LON: HEMO) is not a stock for the faint-hearted. The Main Market company’s share price spiked to 13.4p in late August 2020, and then collapsed to under 3p by mid-May 2021. It then […]